... with adherence to and satisfaction with transdermal rivastigmine treatment. Methods: Sociodemographic, clinical and psychosocial data were collected from 127 patients and their caregivers during the first follow-up visit after prescription. At the second follow-up, data were collected on 110 of the dyads...

...Jacob Penner; Jennie L. Wells; Michael J. Borrie; Sarah M. Woolmore-Goodwin; Robert Bartha Aim: To determine whether 4 months of rivastigmine treatment would result in metabolic changes and whether metabolic changes correlate with changes in cognition in people with Alzheimer's disease (AD...

... of open-label treatment with 9.5 mg/24 h (10 cm 2 ) rivastigmine patch, benefit from a dose increase in a double-blind (DB) comparative trial of two patch doses. Methods: Patients meeting prespecified decline criteria were randomized to receive 9.5 or 13.3 mg/24 h (15 cm 2 ) patch during a 48-week, DB...

...Jason T. Olin; Dag Aarsland; Xiangyi Meng Aims: To investigate the effects of rivastigmine capsule 3–12 mg/day over 24 weeks on activities of daily living (ADLs) in patients with dementia associated with Parkinson’s disease (PDD). Methods: Post hocanalysis of a prospective, multicenter, randomized...

.... Methods: This retrospective analysis used data from a 24-week, randomized, placebo-controlled trial [study ENA713D2320 (IDEAL)] that evaluated rivastigmine patches and capsules in AD patients. Results: At week 24, significant treatment effects versus placebo were seen on the ADCS-CGIC cognitive domain...

... of disease progression and drug effects. The objective was to assess combination therapy of rivastigmine plus memantine by specific neuropsychological tests in patients with mild-to-moderate AD. Methods: 12-week-short multicenter open-label pilot study. Ninety patients with mild-to-moderate AD already...

... Alzheimer’s disease Acetylcholine Circadian rhythm Sleep disorders Cholinesterase inhibitors Galantamine Donepezil Rivastigmine Slow-wave sleep Original Research Article Dement Geriatr Cogn Disord 2006;21:120 129 DOI: 10.1159/000090630 Accepted: July 18, 2005 Published online: January 2, 2006...

... of rivastigmine were more pronounced in AD patients with rapid cognitive decline than in those with slow cognitive decline. This warranted further investigation. Methods: Rapidly and slowly progressing patients were identified by rates of cognitive decline [≧4 points and <4 points, respectively...

... patients, 40 initiated treatment with donepezil, 32 with galantamine, 30 with rivastigmine and 45 were part of a historical sample of the memory clinic patients between 1991 and 1996 that had not been treated with AChEIs. The average age was 73.7 years (SD = 6.9; range = 52–86), 67.3% were women, 78.2...

... E (APOE) genotype could predict cognitive improvement in subjects with probable AD treated with rivastigmine. Methods: 121 subjects with mild to moderate probable AD were treated for 26 weeks with escalating doses of rivastigmine. Outcome measures were change on the MMSE and the ADAS-Cog between...

...Yahya Karaman; Füsun Erdoğan; Emel Köseoğlu; Tayfun Turan; Ali Özdemir Ersoy The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713), in patients with advanced moderate Alzheimer’s disease (AD) was evaluated in a 12-month placebo-controlled study. We aimed...

...A. Kurz; B. van Baelen Data were derived from the Cochrane Collaboration meta-analyses of the efficacies of ginkgo, donepezil, rivastigmine and galantamine on changes in cognitive function in patients with dementia and, where necessary, were transformed to standardized mean differences...

...Ian G. McKeith; Keith A. Wesnes; Elaine Perry; Roberto Ferrara The aim of this analysis of the effects of cholinergic therapy in dementia with Lewy bodies was to determine whether rivastigmine-induced benefits in attention and memory could be predicted by the presence of visual hallucinations...

... the treatment of DLB with acetylcholinesterase inhibitors. Encouraging results have been obtained from studies of DLB patients treated with rivastigmine, donepezil, and galantamine, but large-scale, controlled trials are needed to confirm the efficacy and safety of acetylcholinesterase inhibitors in patients...

...K.A. Wesnes; I.G. McKeith; R. Ferrara; M. Emre; T. Del Ser; P.F. Spano; A. Cicin-Sain; R. Anand; R. Spiegel This study was designed to assess the effects of rivastigmine (Exelon ® ) on the cognitive functioning of patients suffering from dementia with Lewy bodies. This was a prospective, multi...